{Reference Type}: Observational Study
{Title}: The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
{Author}: Rivera-Díaz R;Pozo T;Alfageme F;Díaz Ley B;Osorio GF;Chico R;Vilarrasa E;Silvente C;Ciudad Blanco C;Romaní J;Martorell A;Fernández P;Romero Ferreiro C;Molina Leyva A;
{Journal}: Actas Dermosifiliogr
{Volume}: 114
{Issue}: 9
{Year}: 2023 Oct 16
暂无{DOI}: 10.1016/j.ad.2023.06.013
{Abstract}: <B>BACKGROUND: </B>Hidradenitis suppurativa (HS) is a chronic skin condition causing lesions in which high levels of interleukin (IL)-23 and T-helper 17 cells are found. Adalimumab remains the only approved treatment. Guselkumab, an antibody targeting the p19 protein subunit of extracellular IL-23, is approved for the treatment of moderate-severe psoriasis, but evidence on its efficacy in treating HS is limited.<BR><B>OBJECTIVE: </B>To assess the effectiveness and safety of guselkumab in treating moderate-severe HS under clinical practice conditions.<BR><B>METHODS: </B>A multicentre retrospective observational study was carried out in 13 Spanish Hospitals including adult HS patients treated with guselkumab within a compassionate use programme (March 2020-March 2022). Data referred to patient demographic and clinical characteristics at treatment initiation (baseline), patient-reported outcomes (Numerical Pain Rating Scale [NPRS] and Dermatology Life Quality Index [DLQI]), physician scores (International Hidradenitis Suppurativa Severity Score System [IHS4], HS Physical Global Score [HS-PGA] and Hidradenitis Suppurativa Clinical Response [HiSCR]) were recorded at baseline and at 16, 24, and 48 weeks of treatment.<BR><B>RESULTS: </B>A total of 69 patients were included. Most (84.10%) had severe HS (Hurley III) and had been diagnosed for over ten years (58.80%). The patients had been subjected to multiple non-biological (mean 3.56) or biological (mean 1.78) therapies, and almost 90% of those treated with biologics had received adalimumab. A significant decrease in IHS4, HS-PGA, NPRS, and DLQI scores was observed from baseline to 48 weeks of guselkumab treatment (all p<0.01). HiSCR was achieved in 58.33% and 56.52% of the patients at 16 and 24 weeks, respectively. Overall, 16 patients discontinued treatment, mostly due to inefficacy (n=7) or loss of efficacy (n=3). No serious adverse events were observed.<BR><B>CONCLUSIONS: </B>Our results indicate that guselkumab may be a safe and effective therapeutic alternative for patients with severe HS that fail to respond to other biologics.